BioSpace News Archive

Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced that it has been selected by the European Innovation Council to receive funding of €17.5 million to accelerate the development of ProTcell to treat life-threatening cancers and infection.

Sanofi announced that its Q1 2023 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.

TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic tissue reconstruction, announced today the successful implantations of the first patients with its COAPTIUM Connect Sutureless Nerve Coaptation System as part of its peripheral nerve repair study in Australia.

GreenLight Biosciences confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash.

Surgalign Holdings, Inc. reported operating results for its fourth quarter and full year 2022 ending December 31, 2022.

ResMed announced that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the full year 2022 and provided a business and clinical update.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its full year and fourth quarter 2022 financial results and provided a corporate update.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the fourth quarter and full-year ended December 31, 2022.